Článek se zabývá vztahem inzulinu na rozvoj a progresi nádorových onemocnění a jeho molekulárně-biologickou podstatou se zaměřením na systém IGF. Současně článek zmiňuje horké téma vztahu inzulinu glargin k nádorovým onemocněním.
The article deals with the relation of insulin to development and progression of cancer and its molecular-biology basis with emphasis on IGF system. Concurrently the article mentions the present hot topic of the relation of insulin glargine to cancer.
- Klíčová slova
- glargin,
- MeSH
- diabetes mellitus 2. typu farmakoterapie komplikace MeSH
- financování organizované MeSH
- hodnocení rizik MeSH
- hyperinzulinismus patofyziologie MeSH
- insulinu podobný růstový faktor I metabolismus MeSH
- inzulin analogy a deriváty metabolismus škodlivé účinky MeSH
- lidé MeSH
- nádory etiologie chemicky indukované MeSH
- plošný screening metody organizace a řízení MeSH
- proteiny vázající IGF metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- klinické zkoušky kontrolované MeSH
- přehledy MeSH
Serum levels of adiponectin were measured in patients with benign prostatic hyperplasia and prostate cancer of pT2 and pT3 stage. Adiponectin ELISA assay, immunohistochemistry, and selected metabolic and biochemical parameters measurement was performed in 25 patients with benign prostatic hyperplasia and 43 with prostate cancer (17 patients with organ-confined and 26 patients with locally advanced disease). Serum adiponectin levels did not differ between prostate benign hyperplasia and cancer clinical stage T2, but was significantly higher in pT3 relative to pT2 group (14.51+/-4.92 vs. 21.41+/-8.12, P = 0.003). Tissue immunohistochemistry showed enhanced staining in neoplastic prostate glands and intraepithelial neoplasia relative to benign prostatic hyperplasia without distinction between disease grade and stage. Serum adiponectin levels are higher in locally advanced relative to organ-confined prostate cancer and may thus serve as an auxiliary marker providing further improvement for discrimination between pT2 and pT3 stages.
- MeSH
- adiponektin krev MeSH
- ELISA MeSH
- financování organizované MeSH
- hyperplazie prostaty chirurgie metabolismus patologie MeSH
- imunohistochemie MeSH
- invazivní růst nádoru MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory prostaty chirurgie metabolismus patologie MeSH
- prostatektomie MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
Resistin is a member of adipokine family involved in the regulation of inflammatory reactions and insulin sensitivity. In presented study its possible role in the development of benign prostate hyperplasia and prostate cancer was evaluated. Blood samples and prostate specimens were collected from 26 patients with benign prostate hyperplasia (BPH) and from 42 patients with prostate cancer (PCa) stage pT2 (n=18) and pT3 (n=24). Selected metabolic and biochemical parameters and serum resistin levels were measured and anthropometric measurements were performed as well as tissue immunohistochemistry for resistin. Serum resistin levels did not differ significantly between benign hyperplasia and prostate cancer but in cancer patients there was a trend towards decrease with higher cancer stage. Moreover, serum resistin levels were significantly lower in patients with seminal vesicle invasion in comparison to those without invasion. While in BPH serum resistin levels correlated with insulin resistance, inflammatory status and cortisol, in PCa positive correlation with F/T PSA ratio and cortisol was observed. Tissue immunohistochemistry did not show any differences in staining pattern between benign and neoplastic prostate tissue. We conclude that serum resistin levels do not significantly differ between patients with benign prostate hyperplasia and prostate cancer, but there is a trend towards decrease in resistin serum levels in advanced cancer cases.
- MeSH
- cytokiny MeSH
- epidemiologické studie MeSH
- index tělesné hmotnosti MeSH
- karcinom MeSH
- leptin biosyntéza fyziologie krev MeSH
- lidé MeSH
- mezibuněčné signální peptidy a proteiny fyziologie chemie krev MeSH
- nádory prostaty MeSH
- obezita MeSH
- techniky in vitro MeSH
- tukové buňky MeSH
- Check Tag
- lidé MeSH
Adipocytokines – adipose tissue hormones – have been recognized among others as a potential link between obesity and cancer development. The role of adiponectin in organ limited and locally advanced prostate cancer was studied. Material and methods: Adiponectin ELISA assay, tissue immunohistochemistry and selected biochemical, hormonal and metabolic parameters were meausured in 25 patients with benign prostate hyperplasia and 43 with prostate cancer (17 patients with organ-confined (pT2) and 26 patients with locally advanced disease (pT3)). Results: Serum adiponectin levels did not differ between prostate benign hyperplasia and cancer, but was significantly higher in pT3 in comparison to pT2 group (14.51 ± 4.92 vs. 21.41 ± 8.12, P = 0.003). Tissue immunohistochemistry showed enhanced staining in neoplastic prostate glands and intraepithelial neoplasia relative to benign prostate hyperplasia without correlation to disease grade or stage. Conclusions: Serum adiponectin levels are increased in locally advanced prostate cancer and may thus serve as an auxiliary marker providing futher improvement to PSA for preoperative discrimination between pT2 and pT3 stages.
- MeSH
- cytokiny fyziologie imunologie metabolismus MeSH
- diabetes mellitus enzymologie epidemiologie metabolismus MeSH
- finanční podpora výzkumu jako téma MeSH
- leptin fyziologie imunologie metabolismus MeSH
- lidé MeSH
- mezibuněčné signální peptidy a proteiny fyziologie imunologie metabolismus MeSH
- nádory enzymologie etiologie metabolismus MeSH
- obezita enzymologie metabolismus patofyziologie MeSH
- techniky in vitro MeSH
- tuková tkáň enzymologie metabolismus patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- srovnávací studie MeSH
